Subgroup analyses suggests dual-negative expression of Nrf2 and NQO1 presents superior outcomes for both OS and DFS in advanced-stage NSCLC patients, rather than in early stage NSCLC patients. Here, NQO1 is linked to non-small cell lung carcinoma.